Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19
Status:
Suspended
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1
and 400 mg/day on D2 to D7) and azithromycin (500 mg/ 5 days) to treat mild ambulatory
COVID-19 patients.